{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:59:03Z","timestamp":1772585943585,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG078759"],"award-info":[{"award-number":["R01AG078759"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00198-025-07745-1","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:20:55Z","timestamp":1763731255000},"page":"331-340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A scoping review of real-world evidence generation methods to estimate the safety of type 2 diabetes medications on fracture risk"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3228-8766","authenticated-orcid":false,"given":"Maria C.","family":"Spagnuolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1222-8524","authenticated-orcid":false,"given":"Freddy F.","family":"Shogry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-7541","authenticated-orcid":false,"given":"Nicholas","family":"Bakewell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1122-0071","authenticated-orcid":false,"given":"Kaleen N.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-8530","authenticated-orcid":false,"given":"Andrea M.","family":"Burden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2018-8111","authenticated-orcid":false,"given":"Anisha K.","family":"Hundal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8584-9649","authenticated-orcid":false,"given":"Suzanne M.","family":"Cadarette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"7745_CR1","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1056\/NEJM198212233072604","volume":"307","author":"AR Feinstein","year":"1982","unstructured":"Feinstein AR, Horwitz RI (1982) Double standards, scientific methods, and epidemiologic research. N Engl J Med 307:1611\u20131617. https:\/\/doi.org\/10.1056\/NEJM198212233072604","journal-title":"N Engl J Med"},{"key":"7745_CR2","unstructured":"Designing sound clinical trials that incorporate real-world data | FDA. https:\/\/www.fda.gov\/drugs\/regulatory-science-action\/designing-sound-clinical-trials-incorporate-real-world-data. Accessed 17 Jul 2023"},{"key":"7745_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1056\/NEJMRA1614394\/SUPPL_FILE\/NEJMRA1614394_DISCLOSURES.PDF","volume":"377","author":"TR Frieden","year":"2017","unstructured":"Frieden TR (2017) Evidence for health decision making \u2014 beyond randomized, controlled trials. N Engl J Med 377:465\u2013475. https:\/\/doi.org\/10.1056\/NEJMRA1614394\/SUPPL_FILE\/NEJMRA1614394_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"key":"7745_CR4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2217\/FON-2020-0951","volume":"17","author":"B Nazha","year":"2020","unstructured":"Nazha B, Yang JCH, Owonikoko TK (2020) Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer. Future Oncol 17:965\u2013977. https:\/\/doi.org\/10.2217\/FON-2020-0951","journal-title":"Future Oncol"},{"key":"7745_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/J.AMJCARD.2020.05.011","volume":"129","author":"JB Kostis","year":"2020","unstructured":"Kostis JB, Dobrzynski JM (2020) Limitations of randomized clinical trials. Am J Cardiol 129:109\u2013115. https:\/\/doi.org\/10.1016\/J.AMJCARD.2020.05.011","journal-title":"Am J Cardiol"},{"key":"7745_CR6","unstructured":"Real-World Evidence | FDA. https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence. Accessed 6 Jun 2023"},{"key":"7745_CR7","unstructured":"Submitting documents using real-world data and real-world evidence to FDA for drug and biological products | FDA. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/submitting-documents-using-real-world-data-and-real-world-evidence-fda-drug-and-biological-products. Accessed 18 Apr 2023"},{"key":"7745_CR8","unstructured":"Elements of real world data\/evidence quality throughout the prescription drug product life cycle - Canada.ca. https:\/\/www.canada.ca\/en\/services\/health\/publications\/drugs-health-products\/real-world-data-evidence-drug-lifecycle-report.html. Accessed 18 Apr 2023"},{"key":"7745_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/CPT.1426","volume":"106","author":"A Cave","year":"2019","unstructured":"Cave A, Kurz X, Arlett P (2019) Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther 106:36\u201339. https:\/\/doi.org\/10.1002\/CPT.1426","journal-title":"Clin Pharmacol Ther"},{"key":"7745_CR10","doi-asserted-by":"publisher","DOI":"10.4212\/CJHP.V68I3.1457","volume":"68","author":"SM Cadarette","year":"2015","unstructured":"Cadarette SM, Wong L (2015) An introduction to health care administrative data. Can J Hosp Pharm 68:232. https:\/\/doi.org\/10.4212\/CJHP.V68I3.1457","journal-title":"Can J Hosp Pharm"},{"key":"7745_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1503\/CMAJ.080486","volume":"180","author":"YK Loke","year":"2009","unstructured":"Loke YK, Singh S, Furberg CD (2009) Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Can Med Assoc J 180:32\u201339. https:\/\/doi.org\/10.1503\/CMAJ.080486","journal-title":"Can Med Assoc J"},{"key":"7745_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 157:107843. https:\/\/doi.org\/10.1016\/j.diabres.2019.107843","journal-title":"Diabetes Res Clin Pract"},{"key":"7745_CR13","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/S0140-6736(05)61032-X","volume":"365","author":"M Stumvoll","year":"2005","unstructured":"Stumvoll M, Goldstein BJ, Van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333. https:\/\/doi.org\/10.1016\/S0140-6736(05)61032-X","journal-title":"Lancet"},{"key":"7745_CR14","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2337\/DC13-2289","volume":"37","author":"C Hampp","year":"2014","unstructured":"Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK (2014) Use of antidiabetic drugs in the U.S., 2003\u20132012. Diabetes Care 37:1367\u20131374. https:\/\/doi.org\/10.2337\/DC13-2289","journal-title":"Diabetes Care"},{"key":"7745_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jcjd.2020.08.001","volume":"44","author":"L Lipscombe","year":"2020","unstructured":"Lipscombe L, Butalia S, Dasgupta K et al (2020) Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Can J Diabetes 44:575\u2013591. https:\/\/doi.org\/10.1016\/j.jcjd.2020.08.001","journal-title":"Can J Diabetes"},{"key":"7745_CR16","doi-asserted-by":"publisher","unstructured":"Tan Y, Ling J, Wong M et al (2018) Type 1 and 2 diabetes mellitus: a review on current treatment approach and gene therapy as potential intervention. https:\/\/doi.org\/10.1016\/j.dsx.2018.10.008","DOI":"10.1016\/j.dsx.2018.10.008"},{"key":"7745_CR17","unstructured":"For Health Professionals - association between long-term treatment with Actos (pioglitazone hydrochloride) tablets for type 2 diabetes mellitus and fractures in women - Canada.ca. https:\/\/recalls-rappels.canada.ca\/en\/alert-recall\/health-professionals-association-between-long-term-treatment-actos-pioglitazone. Accessed 18 Apr 2023"},{"key":"7745_CR18","unstructured":"FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density | FDA. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet. Accessed 18 Apr 2023"},{"key":"7745_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S2213-8587(21)00347-8","volume":"10","author":"LC Hofbauer","year":"2022","unstructured":"Hofbauer LC, Busse B, Eastell R et al (2022) Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diabetes Endocrinol 10:207\u2013220. https:\/\/doi.org\/10.1016\/S2213-8587(21)00347-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7745_CR20","doi-asserted-by":"publisher","DOI":"10.21037\/ATM.2019.09.51","volume":"7","author":"C Guja","year":"2019","unstructured":"Guja C, Guja L, Miulescu RD (2019) Effect of type 2 diabetes medications on fracture risk. Ann Transl Med 7:580\u2013580. https:\/\/doi.org\/10.21037\/ATM.2019.09.51","journal-title":"Ann Transl Med"},{"key":"7745_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/J.JCLINEPI.2010.07.007","volume":"64","author":"AH Warriner","year":"2011","unstructured":"Warriner AH, Patkar NM, Curtis JR et al (2011) Which fractures are most attributable to osteoporosis? J Clin Epidemiol 64:46\u201353. https:\/\/doi.org\/10.1016\/J.JCLINEPI.2010.07.007","journal-title":"J Clin Epidemiol"},{"key":"7745_CR22","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.11124\/JBIES-20-00518","volume":"19","author":"KN Hayes","year":"2021","unstructured":"Hayes KN, Hundal AK, Cadarette SM (2021) Observational study methods used to assess pharmacotherapy effects of type 2 diabetes on fracture risk: a scoping review protocol. JBI Evid Synth 19:3129\u20133141. https:\/\/doi.org\/10.11124\/JBIES-20-00518","journal-title":"JBI Evid Synth"},{"key":"7745_CR23","doi-asserted-by":"publisher","unstructured":"(2020) Chapter 11: Scoping reviews. JBI Manual for Evidence Synthesis. https:\/\/doi.org\/10.46658\/JBIMES-20-12","DOI":"10.46658\/JBIMES-20-12"},{"key":"7745_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/J.JBI.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R et al (2009) Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377\u2013381. https:\/\/doi.org\/10.1016\/J.JBI.2008.08.010","journal-title":"J Biomed Inform"},{"key":"7745_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/J.JBI.2019.103208","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform. https:\/\/doi.org\/10.1016\/J.JBI.2019.103208","journal-title":"J Biomed Inform"},{"key":"7745_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.861422","author":"ZK Al-Mashhadi","year":"2022","unstructured":"Al-Mashhadi ZK, Viggers R, Starup-Linde J et al (2022) SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: a nationwide cohort study. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2022.861422","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7745_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000154","volume":"6","author":"IJ Douglas","year":"2009","unstructured":"Douglas IJ, Evans SJ, Pocock S, Smeeth L (2009) The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 6:e1000154. https:\/\/doi.org\/10.1371\/journal.pmed.1000154","journal-title":"PLoS Med"},{"key":"7745_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ONCOLO\/OYAC114","volume":"27","author":"L Azoulay","year":"2022","unstructured":"Azoulay L (2022) Rationale, strengths, and limitations of real-world evidence in oncology: a Canadian review and perspective. Oncologist 27:e731. https:\/\/doi.org\/10.1093\/ONCOLO\/OYAC114","journal-title":"Oncologist"},{"key":"7745_CR29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/pds.4372","volume":"27","author":"L Pazzagli","year":"2018","unstructured":"Pazzagli L, Linder M, Zhang M et al (2018) Methods for time-varying exposure related problems in pharmacoepidemiology: an overview. Pharmacoepidemiol Drug Saf 27:148\u2013160. https:\/\/doi.org\/10.1002\/pds.4372","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7745_CR30","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/NRENDO.2016.86","volume":"12","author":"AA Tahrani","year":"2016","unstructured":"Tahrani AA, Barnett AH, Bailey CJ (2016) Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 12:566\u2013592. https:\/\/doi.org\/10.1038\/NRENDO.2016.86","journal-title":"Nat Rev Endocrinol"},{"key":"7745_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.18773\/AUSTPRESCR.2016.039","volume":"39","author":"N Keks","year":"2016","unstructured":"Keks N, Hope J, Keogh S (2016) Switching and stopping antidepressants. Aust Prescr 39:76. https:\/\/doi.org\/10.18773\/AUSTPRESCR.2016.039","journal-title":"Aust Prescr"},{"key":"7745_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.861422","volume":"13","author":"Z Kejlberg Al-Mashhadi","year":"2022","unstructured":"Kejlberg Al-Mashhadi Z, Viggers R, Starup-Linde J et al (2022) SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: a nationwide cohort study. Front Endocrinol 13:861422. https:\/\/doi.org\/10.3389\/fendo.2022.861422","journal-title":"Front Endocrinol"},{"key":"7745_CR33","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/clpt.2011.235","volume":"90","author":"S Schneeweiss","year":"2011","unstructured":"Schneeweiss S, Gagne JJ, Glynn RJ et al (2011) Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther 90:777\u2013790. https:\/\/doi.org\/10.1038\/clpt.2011.235","journal-title":"Clin Pharmacol Ther"},{"key":"7745_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-019-0695-y","volume":"19","author":"G Prada-Ramallal","year":"2019","unstructured":"Prada-Ramallal G, Takkouche B, Figueiras A (2019) Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review. BMC Med Res Methodol 19:53. https:\/\/doi.org\/10.1186\/s12874-019-0695-y","journal-title":"BMC Med Res Methodol"},{"key":"7745_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70000","author":"KK S\u00f8rensen","year":"2024","unstructured":"S\u00f8rensen KK, Gerds TA, K\u00f8ber L et al (2024) Comparing glucagon-like peptide-1 receptor agonists versus metformin in drug-naive patients: a nationwide cohort study. J Diabetes. https:\/\/doi.org\/10.1111\/1753-0407.70000","journal-title":"J Diabetes"},{"key":"7745_CR36","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/pds.4107","volume":"26","author":"S Suissa","year":"2017","unstructured":"Suissa S, Moodie EEM, Dell\u2019Aniello S (2017) Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiol Drug Saf 26:459\u2013468. https:\/\/doi.org\/10.1002\/pds.4107","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7745_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078483","volume":"385","author":"EL Fu","year":"2024","unstructured":"Fu EL, Wexler DJ, Cromer SJ et al (2024) SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study. BMJ e078483. https:\/\/doi.org\/10.1136\/bmj-2023-078483","journal-title":"BMJ"},{"key":"7745_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/EE9.0000000000000177","volume":"5","author":"DA Savitz","year":"2021","unstructured":"Savitz DA (2021) Epidemiology and biological plausibility in assessing causality. Environ Epidemiol 5:e177. https:\/\/doi.org\/10.1097\/EE9.0000000000000177","journal-title":"Environ Epidemiol"},{"key":"7745_CR39","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/PDS.4295","volume":"26","author":"SV Wang","year":"2017","unstructured":"Wang SV, Schneeweiss S, Berger ML et al (2017) Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies V1.0. Pharmacoepidemiol Drug Saf 26:1018\u20131032. https:\/\/doi.org\/10.1002\/PDS.4295","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7745_CR40","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00198-022-06395-x","volume":"33","author":"N Konstantelos","year":"2022","unstructured":"Konstantelos N, Rzepka AM, Burden AM et al (2022) Fracture definitions in observational osteoporosis drug effects studies that leverage healthcare administrative (claims) data: a scoping review. Osteoporos Int 33:1837\u20131844","journal-title":"Osteoporos Int"},{"key":"7745_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.735824","author":"Y-S Zhang","year":"2021","unstructured":"Zhang Y-S, Zheng Y-D, Yuan Y et al (2021) Effects of anti-diabetic drugs on fracture risk: a systematic review and network meta-analysis. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2021.735824","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7745_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110082","volume":"192","author":"W-H Tsai","year":"2022","unstructured":"Tsai W-H, Kong S-K, Lin C-L et al (2022) Risk of fracture caused by anti-diabetic drugs in individuals with type 2 diabetes: a network meta-analysis. Diabetes Res Clin Pract 192:110082. https:\/\/doi.org\/10.1016\/j.diabres.2022.110082","journal-title":"Diabetes Res Clin Pract"},{"key":"7745_CR43","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1136\/BMJ.K3532","volume":"363","author":"SM Langan","year":"2018","unstructured":"Langan SM, Schmidt SA, Wing K et al (2018) The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 363:3532. https:\/\/doi.org\/10.1136\/BMJ.K3532","journal-title":"BMJ"},{"key":"7745_CR44","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/aje\/kwae087","volume":"193","author":"SV Wang","year":"2024","unstructured":"Wang SV, Potteg\u00e5rd A (2024) Building transparency and reproducibility into the practice of pharmacoepidemiology and outcomes research. Am J Epidemiol 193:1625\u20131631. https:\/\/doi.org\/10.1093\/aje\/kwae087","journal-title":"Am J Epidemiol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07745-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07745-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07745-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:08:57Z","timestamp":1772582937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07745-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7745"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07745-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KNH has received investigator-initiated grant funding paid directly to Brown University for investigator-initiated research from Sanofi, Genentech, and GlaxoSmithKline for research on influenza vaccination in nursing homes, influenza outbreak control, and shingles vaccination in nursing homes, respectively. MCS, FFS, SP, NB, AMB, AKH, and SMC declare they have no conflicts of interest. Written permission has been obtained by all authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}